Mimura Yuji, Kobayashi Aya, Utazu Haruhiko, Matsumoto Yuki, Mizusawa Hiroya
Department of Urology, NHO Shinshu Ueda Medical Center Ueda Nagano Japan.
Department of Dermatology Shinshu Ueda Medical Center Ueda Nagano Japan.
IJU Case Rep. 2022 Dec 2;6(2):111-115. doi: 10.1002/iju5.12562. eCollection 2023 Mar.
Enfortumab vedotin is a novel drug for locally advanced or metastatic urothelial carcinoma, but it is associated with a high incidence of skin reactions (up to 47.0%).
A 71-year-old male was administered enfortumab vedotin for bladder cancer associated with lymph node metastases. Slight erythema of the upper limbs appeared on Day 5. Erythema gradually worsened. On Day 8, second administration was performed. On Day 12, based on the extents of blisters, erosion, and epidermolysis, a diagnosis of toxic epidermal necrolysis was made. The patient died of multiple organ failure on Day 18.
As serious cutaneous toxicity may appear early after the start of administration, it is important to consider the timing of the second administration of the initial course carefully. In cases of skin reaction, reduction or discontinuation should be considered.
恩杂鲁胺是一种用于局部晚期或转移性尿路上皮癌的新型药物，但它与皮肤反应的高发生率相关（高达47.0%）。
一名71岁男性因膀胱癌伴淋巴结转移接受恩杂鲁胺治疗。第5天出现上肢轻度红斑。红斑逐渐加重。第8天进行了第二次给药。第12天，根据水疱、糜烂和表皮松解的程度，诊断为中毒性表皮坏死松解症。患者于第18天死于多器官功能衰竭。
由于严重的皮肤毒性可能在给药开始后早期出现，因此仔细考虑初始疗程第二次给药的时机很重要。在出现皮肤反应的情况下，应考虑减量或停药。
